S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial-Reference-Cited by-同舟云学术

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

Published:2018-03 Issue:3 Volume:29 Page:624-631
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Yamada Y.,Denda T.,Gamoh M.,Iwanaga I.,Yuki S.,Shimodaira H.,Nakamura M.,Yamaguchi T.,Ohori H.,Kobayashi K.,Tsuda M.,Kobayashi Y.,Miyamoto Y.,Kotake M.,Shimada K.,Sato A.,Morita S.,Takahashi S.,Komatsu Y.,Ishioka C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/3/624/24530928/mdx816.pdf

Reference14 articles.

1. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G);Yamazaki;Ann Oncol,2016

2. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer;Cassidy;J Clin Oncol,2008

3. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial;André;J Clin Oncol,2009

4. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study;Fuchs;J Clin Oncol,2007

5. S-1 for the treatment of gastrointestinal cancer;Satoh;Expert Opin Pharmacother,2012

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells;Cancer Chemotherapy and Pharmacology;2024-09-14

2. A network meta-analysis of efficacy and safety for first-line and maintenance therapies in patients with unresectable colorectal liver metastases;Frontiers in Pharmacology;2024-07-26

3. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial;International Journal of Colorectal Disease;2024-06-11

4. Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study);Acta Oncologica;2024-05-02

5. Multimodal Treatment of Metastatic Rectal Cancer in a Young Patient: Case Report and Literature Review;Medicina;2024-04-24